Intraperitoneal antineoplastic drug delivery: rationale and results (Q35121705)

6 August 2017

title

Intraperitoneal antineoplastic drug delivery: rationale and results (English)

1 reference

6 August 2017

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12732164

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

30 December 2023

Maurie Markman

1 reference

6 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12732164

30 December 2023

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://api.elsevier.com/content/article/PII:S147020450301074X?httpAccept=text/xml

1 reference

DOI

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

https://api.elsevier.com/content/article/PII:S147020450301074X?httpAccept=text/plain

30 December 2023

1 reference

DOI

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Lancet Oncology Commission

30 December 2023

published in

1 reference

6 August 2017

1 reference

6 August 2017

1 reference

6 August 2017

page(s)

277-283

1 reference

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

An assessment of the long-term results of controlling the reaccumulation of malignant effusions using intracavity bleomycin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal therapy for treatment of malignant disease principally confined to the peritoneal cavity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal cisplatin with systemic thiosulfate protection

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Preliminary observations of intraperitoneal carboplatin pharmacokinetics during a phase I study of the Northern California Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Pharmacokinetics of carboplatin after intraperitoneal administration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase I trial of intraperitoneal taxol: a Gynecoloic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Penetration and binding of vinblastine and 5-fluorouracil in cellular spheroids.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Characteristics of patients with small-volume residual ovarian cancer unresponsive to cisplatin-based ip chemotherapy: Lessons learned from a gynecologic oncology group phase II trial of ip cisplatin and recombinant α-interferon

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal administration of cisplatin and 5-fluorouracil in residual ovarian cancer: a Phase II Gynecologic Oncology Group trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase II trial of intraperitoneal mitoxantrone in the management of refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal interferon-alpha in residual ovarian carcinoma: a phase II gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal recombinant interferon gamma in ovarian cancer patients with residual disease at second-look laparotomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal carboplatin in the treatment of minimal residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal carboplatin: favorable results in women with minimal residual ovarian cancer after cisplatin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Evaluation of survival after second-line intraperitoneal cisplatin-based chemotherapy for advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal chemotherapy for ovarian carcinoma: results of long-term follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with Stage II-IV epithelial ovarian cancer following negative surgical assessment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

High-Intensity Intravenous Cyclophosphamide and Cisplatin, Interim Surgical Debulking, and Intraperitoneal Cisplatin in Advanced Ovarian Carcinoma: A Pilot Trial with Ten-Year Follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Infectious peritonitis in patients receiving intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Phase 2 trial of intraperitoneal carboplatin and etoposide as salvage treatment of advanced epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Evidence supporting the superiority of intraperitoneal cisplatin compared to intraperitoneal carboplatin for salvage therapy of small-volume residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Pentetration of carboplatin and cisplatin into rat peritoneal tumor nodules after intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Prophylaxis with carbon-adsorbed mitomycin against peritoneal recurrence of gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Adjuvant intraperitoneal chemotherapy with carbon-adsorbed mitomycin in patients with gastric cancer: results of a randomized multicenter trial of the Austrian Working Group for Surgical Oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Prospective randomized trial of early postoperative intraperitoneal chemotherapy as an adjuvant to resectable gastric cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Curative treatment of peritoneal carcinomatosis arising from colorectal cancer by complete resection and intraperitoneal chemotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Cisplatin administered by the intracavitary route as treatment for malignant mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Early peritoneal mesothelioma: a treatable malignancy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Long-term survival in peritoneal mesothelioma. The role of radiotherapy and combined modality treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Is There a Role for Intraperitoneal Therapy in the Management of Gastrointestinal Malignancies?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Patients with pseudomyxoma peritonei associated with disseminated peritoneal adenomucinosis have a significantly more favorable prognosis than patients with peritoneal mucinous carcinomatosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2803%2901074-X

7 January 2021

Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Flow cytometry studies of intracellular adriamycin in multicell spheroids in vitro

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Pharmacokinetics of adriamycin and tissue penetration in murine ovarian cancer

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

Prospective, randomized trial of intravenous versus intraperitoneal 5-fluorouracil in patients with advanced primary colon or rectal cancer

30 December 2023

1 reference

https://api.crossref.org/works/10.1016/S1470-2045(03)01074-X

30 December 2023

Identifiers

DOI

1 reference

6 August 2017

1 reference